Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

FRNM

Freenome Inc

10.77

Jul 28 • 3:59 PM ET -0.61 (-5.36%)

10.77

Aftermarket • 4:04 PM ET 0.00 (0.00%)

Healthcare Diagnostics & Research USA Micro NASD

Jul 27, 8:08 AMFreenome wins FDA approval for SimpleScreen CRC blood test, triggering $100 million milestone payment from Abbott

Held by: TMED

Scroll to Statements

Index	-
Market Cap	111.08M
Enterprise Value	110.64M
Income	-0.76M
Sales	0.00M
Book/sh	7.64
Cash/sh	0.04
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	3
IPO	Jun 12, 2024

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	1.41
P/C	252.45
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	0.20
Current Ratio	0.20
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-0.07
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-123.69%
Sales Y/Y TTM	-
EPS Q/Q	-116.28%
Sales Q/Q	-
Earnings	-
EPS/Sales Surpr.	- -

Insider Own	30.95%
Insider Trans	0.00%
Inst Own	-
Inst Trans	-
ROA	-0.86%
ROE	-0.92%
ROIC	-0.97%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-6.53%
SMA50	-4.57%
SMA200	-8.11%
Trades

Shs Outstand	8.16M
Shs Float	5.02M
Short Float	-
Short Ratio	-
Short Interest	-
52W High	14.47 -25.57%
52W Low	9.95 8.24%
Volatility	16.35% 6.91%
ATR (14)	0.88
RSI (14)	41.28
Beta	0.32
Rel Volume	3.92
Avg Volume	191.65K
Volume	751,270

Perf Week	-17.22%
Perf Month	-1.46%
Perf Quarter	-4.10%
Perf Half Y	-24.15%
Perf YTD	-17.34%
Perf Year	1.70%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	-
Target Price	-
Prev Close	11.38
Price	10.77
Change	-5.36%

Jul-27-26 08:00AM

FDA Approves Freenome's SimpleScreen CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.

(GlobeNewswire)

Freenome, Inc. operates as a biotechnology company. It engages in the development of an early cancer detection platform. The company was founded in 2014 and is headquartered in New York, NY.

CEO & DirectorMr. Aaron Elliott Ph.D.

MHSMr. Cheng-Ho Lin M.D.

Chief Legal OfficerMr. Thomas F. Fitzpatrick J.D.

MSHRMs. Julie Tran M.B.A.

Senior Vice President of Regulatory & QualityMs. Sally Howard J.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

FRNM

Freenome Inc

Upgrade your Finviz experience